Galera Therapeutics, Inc.

Biotechnology • Healthcare • Malvern, PA, United States • GRTX (OQB)

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

610 725 1500 101 Lindenwood Drive, Malvern, PA 19355, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance

Yahoo Finance • Oct 22

Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz

citybiz • Oct 22

Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals

The Business Journals • Oct 22

Why Is Galera Therapeutics (GRTX) Stock Down 83% Today? - InvestorPlace

InvestorPlace • Aug 10

Galera Therapeutics settles lawsuit for $975,000 - Investing.com

Investing.com • Aug 8

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Galera Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Galera Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Galera Therapeutics, Inc. have?

Galera Therapeutics, Inc. has approximately 3 employees.

What industry is Galera Therapeutics, Inc. in?

Galera Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Galera Therapeutics, Inc. a publicly traded company?

Yes, Galera Therapeutics, Inc. is publicly traded under the ticker symbol GRTX on the OQB. The company has a market capitalization of approximately $0.00 billion.

Where is Galera Therapeutics, Inc. headquartered?

Galera Therapeutics, Inc. is headquartered in Malvern, PA, United States at 101 Lindenwood Drive, Malvern, PA 19355, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.